Vanguard Group Inc Relmada Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,256,705 shares of RLMD stock, worth $490,114. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,256,705

Previous 1,256,705 -0.0%

Holding current value

$490,114

Previous $3.77 Million 7.98%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$3.1 - $6.8 $167,710 - $367,880	-54,100 Reduced 4.13%	1,256,705 $5.84 Million
Q4 2023 Feb 14, 2024	BUY	$2.45 - $4.22 $1,886 - $3,249	770 Added 0.06%	1,310,805 $5.43 Million
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $432,775 - $690,101	-194,944 Reduced 12.95%	1,310,035 $3.22 Million
Q1 2023 May 15, 2023	SELL	$2.24 - $4.76 $26,882 - $57,124	-12,001 Reduced 0.79%	1,504,979 $3.4 Million
Q4 2022 Feb 10, 2023	BUY	$2.17 - $35.84 $158,453 - $2.62 Million	73,020 Added 5.06%	1,516,980 $5.29 Million
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $382,982 - $774,754	20,928 Added 1.47%	1,443,960 $53.5 Million
Q2 2022 Aug 12, 2022	BUY	$16.5 - $30.34 $1.63 Million - $3 Million	99,018 Added 7.48%	1,423,032 $27 Million
Q1 2022 May 13, 2022	BUY	$16.72 - $26.99 $1.66 Million - $2.68 Million	99,113 Added 8.09%	1,324,014 $35.7 Million
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $5.25 Million - $8.32 Million	310,178 Added 33.91%	1,224,901 $27.6 Million
Q3 2021 Nov 12, 2021	BUY	$21.86 - $34.77 $3.12 Million - $4.97 Million	142,947 Added 18.52%	914,723 $24 Million
Q2 2021 Aug 13, 2021	BUY	$29.55 - $39.15 $22.8 Million - $30.2 Million	771,776 New	771,776 $24.7 Million

Others Institutions Holding RLMD

# of Institutions

Shares Held

11.5M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.2M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Relmada Therapeutics, Inc. Transaction History